Cargando…
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
Neuroblastoma (NB) is the most common solid tumor of the neural crest cell origin in children and has a poor prognosis in high-risk patients. The oncogene MYCN was found to be amplified at extremely high levels in approximately 20% of neuroblastoma cases. In recent years, research on the targeted hy...
Autores principales: | Jia, Si-Qi, Zhuo, Ran, Zhang, Zi-Mu, Yang, Yang, Tao, Yan-Fang, Wang, Jian-Wei, Li, Xiao-Lu, Xie, Yi, Li, Gen, Wu, Di, Chen, Yan-Ling, Yu, Juan-Juan, Feng, Chen-xi, Li, Zhi-Heng, Zhou, Rong-Fang, Yang, Ran-Dong, Yang, Peng-Cheng, Zhou, Bi, Wan, Xiao-Mei, Wu, Yu-Meng, Jiao, Wan-Yan, Zhou, Ni-Na, Fang, Fang, Pan, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691391/ https://www.ncbi.nlm.nih.gov/pubmed/36438198 http://dx.doi.org/10.1155/2022/7945884 |
Ejemplares similares
-
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
por: Zhang, Kunlong, et al.
Publicado: (2022) -
BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma
por: Chen, Yan-Ling, et al.
Publicado: (2022) -
The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage
por: Zhu, Xingfei, et al.
Publicado: (2023) -
Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood–brain barrier integrity
por: Liu, Lei, et al.
Publicado: (2022) -
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
por: Wang, Wenyu, et al.
Publicado: (2021)